Medindia3h
Study Finds Invisible Gut Inflammation in Psoriasis Patients
Discover the hidden inflammation in psoriasis patients' intestines, its link to leaky gut, and the increased risk of Crohn's ...
Inflammation may explain stomach problems in psoriasis sufferers
People with the skin condition psoriasis often have invisible inflammation in the small intestine with an increased ...
Psoriasis Drugs Market To Reach USD 52.34 Billion By 2033, Growing At A 11.50% CAGR
psoriasis drugs market is expected to expand significantly, growing from an estimated USD 19.65 billion in 2024 ...
News Medical on MSN22h
Inflammation may explain stomach problems in psoriasis sufferers, reveals research
People with the skin condition psoriasis often have invisible inflammation in the small intestine with an increased ...
Popular weight loss drugs could be cheaper for some Americans: What you need to know
If successful, the result could be lower Medicare Part D prices for drugs used to create a variety of conditions, such as ...
Inflammation behind leaky gut in people with skin disease: Study
People with psoriasis -- a skin condition -- often have invisible inflammation in the small intestine that increases their ...
3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever
Investors seeking a steadily growing passive income stream want to turn their heads toward the healthcare sector. Unlike with ...
The Nassau Guardian1h
What your feet say about your health
Your feet can tell you a lot about your general health condition or warn you of underlying health conditions. From pesky foot ...
Interleukin inhibitors remain a strong growth driver in dermatology
Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.
Buy Sun Pharma; target of Rs 2400: Emkay Global Financial
Emkay Global Financial is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 2400 in its ...
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)
SAN DIEGO, CA and SOUTH SAN FRANCISCO, CA / / January 21, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ('Dermata') and Revance Therapeutics, Inc. (Nasdaq: RVNC) ('Revance' together ...